Tolerance toward tumor antigens, which are shared by normal tissues, have often limited the efficacy of cancer vaccines. However, wild type epitopes can be tweaked to activate cross-reactive T-cell clones, resulting in antitumor activity. The design of these analogs (i.e., heteroclitic peptides) can be difficult and time-consuming since no automated in silico tools are available. Hereby we describe the development of an in silico framework to improve the selection of heteroclitic peptides. The Epitope Discovery and Improvement System (EDIS) was first validated by studying the model antigen SIINFEKL. Based on artificial neural network (ANN) predictions, we selected two mutant analogs that are characterized by an increased MHC-I binding affinity (SIINFAKL) or increased TCR stimulation (SIIWFEKL). Therapeutic vaccination using optimized peptides resulted in enhanced antitumor activity and against B16.OVA melanomas in vivo. The translational potential of the EDIS platform was further demonstrated by studying the melanoma-associated antigen tyrosinase related protein 2 (TRP2). Following therapeutic immunization with the EDIS-derived epitope SVYDFFAWL, a significant reduction in the growth of established B16.F10 tumors was observed, suggesting a break in the tolerance toward the wild type epitope. Finally, we tested a multi vaccine approach, demonstrating that combination of wild type and mutant epitopes targeting both TRP2 and OVA antigens increases the antitumor response. In conclusion, by taking advantage of available prediction servers and molecular dynamics simulations, we generated an innovative platform for studying the initial sequences and selecting lead candidates with improved immunological features. Taken together, EDIS is the first automated algorithm-driven platform to speed up the design of heteroclitic peptides that can be publicly queried online.

Cancer Gene Therapy Group Department of Oncology Faculty of Medicine University Helsinki Helsinki Finland

CEINGE Biotecnologie Avanzate S C a R L Naples Italy

Centre for Drug Research at the Division of Pharmaceutical Biosciences Faculty of Pharmacy University of Helsinki Helsinki Finland

Department of Molecular Medicine and Medical Biotechnologies University of Naples Federico 2 Naples Italy

Department of Pharmacy Center for Drug Research Pharmaceutical Biology Ludwig Maximilians University of Munich Munich Germany

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Prague 6 Czech Republic

Laboratory of Immunovirotherapy Drug Research Program University of Helsinki Helsinki Finland

Targovax Oy Helsinki Finland

TILT Biotherapeutics Helsinki Finland

Oncoimmunology. 2017 Oct 6;6(10):e1389146. doi: 10.1080/2162402X.2017.1389146. PubMed   Cervera-Carascon, Victor [corrected to Cervera-Carrascon, Victor]

Zobrazit více v PubMed

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R et al.. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012. August; 18(8):1254–61; PMID: 22842478; https://doi.org/10.1038/nm.2883 PubMed DOI

Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012; 1(9):1557-76; PMID: 23264902; https://doi.org/10.4161/onci.22428 PubMed DOI PMC

Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW et al.. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005; 174(5):3080-6; PMID: 15728523; https://doi.org/10.4049/jimmunol.174.5.3080 PubMed DOI

Menez-Jamet J, Gallou C, Rougeot A, Kosmatopoulos K. Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med 2016; 4(14):266; PMID: 27563653; https://doi.org/10.21037/atm.2016.05.15 PubMed DOI PMC

Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N. Identifying individual T Cell receptors of optimal avidity for tumor antigens. Front Immunol 2015; 6:582; PMID: 26635796; https://doi.org/10.3389/fimmu.2015.00582 PubMed DOI PMC

Daniel C, Nolting J, von Boehmer H. Mechanisms of self-nonself discrimination and possible clinical relevance. Immunotherapy 2009; 1(4):631-44; PMID: 20582233; https://doi.org/10.2217/imt.09.29 PubMed DOI PMC

Yutoku M, Fuji H, Grossberg AL, Pressman D. An experimental model for evaluation of factors in tumor escape from immunological attack. Cancer Res 1975; 35(3):734-9; PMID: 1116132 PubMed

Bright RK, Bright JD, Byrne JA. Overexpressed oncogenic tumor-self antigens. Hum Vaccin Immunother 2014; 10(11):3297-305; PMID: 25483660; https://doi.org/10.4161/hv.29475 PubMed DOI PMC

Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12(4):269-81; PMID: 22437939; https://doi.org/10.1038/nri3191 PubMed DOI PMC

Regner M. Cross-reactivity in T-cell antigen recognition. Immunol Cell Biol 2001; 79(2):91-100; PMID: 11349650; https://doi.org/10.1046/j.1440-1711.2001.00994.x PubMed DOI

Chen HD, Fraire AE, Joris I, Brehm MA, Welsh RM, Selin LK. Memory CD8+ T cells in heterologous antiviral immunity and immunopathology in the lung. Nat Immunol 2001; 2(11):1067-76; PMID: 11668342; https://doi.org/10.1038/ni727 PubMed DOI

Selin LK, Cornberg M, Brehm MA, Kim SK, Calcagno C, Ghersi D, Puzone R, Celada F, Welsh RM. CD8 memory T cells: cross-reactivity and heterologous immunity. Semin Immunol 2004; 16(5):335-47; PMID: 15528078; https://doi.org/10.1016/j.smim.2004.08.014 PubMed DOI PMC

Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, Antia R. Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire. Front Immunol 2013; 4:485; PMID: 24421780; https://doi.org/10.3389/fimmu.2013.00485 PubMed DOI PMC

Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998; 19(9):395-404; PMID: 9745202; https://doi.org/10.1016/S0167-5699(98)01299-7 PubMed DOI

Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC et al.. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520(7549):692-6; PMID: 25901682; https://doi.org/10.1038/nature14426 PubMed DOI PMC

Chen JL, Dunbar PR, Gileadi U, Jäger E, Gnjatic S, Nagata Y, Stockert E, Panicali DL, Chen YT, Knuth A et al.. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000; 165(2):948-55; PMID: 10878370; https://doi.org/10.4049/jimmunol.165.2.948 PubMed DOI

Chen S, Li Y, Depontieu FR, McMiller TL English AM, Shabanowitz J, Kos F, Sidney J, Sette A, Rosenberg SA et al.. Structure-based design of altered MHC Class II-restricted peptide ligands with heterogeneous immunogenicity. J Immunol 2013. November 15; 191(10), 5097-106; PMID:24108701; https://doi.org/10.4049/jimmunol.1300467 PubMed DOI PMC

Hoppes R, Oostvogels R, Luimstra JJ, Wals K, Toebes M, Bies L, Ekkebus R, Rijal P, Celie PH, Huang JH et al.. Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes. J Immunol 2014; 193(10):4803-13; PMID: 25311806; https://doi.org/10.4049/jimmunol.1400800 PubMed DOI PMC

Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, Bhachu S, Ye X, Deck RR, O'Day SJ. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126(12):2658-63; PMID: 16946711; https://doi.org/10.1038/sj.jid.5700545 PubMed DOI

Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184(6):2207-16; PMID: 8976176; https://doi.org/10.1084/jem.184.6.2207 PubMed DOI PMC

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998; 161(12):6970-6; PMID: 9862732 PubMed

Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med 2016; 8(1):33; PMID: 27029192; https://doi.org/10.1186/s13073-016-0288-x PubMed DOI PMC

Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009; 61(1):1-13; PMID: 19002680; https://doi.org/10.1007/s00251-008-0341-z PubMed DOI PMC

Calis JJ, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Keşmir C, Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol 2013; 9(10):e1003266; PMID: 24204222; https://doi.org/10.1371/journal.pcbi.1003266 PubMed DOI PMC

Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC Class-I molecules. Annu Rev Immunol 1993; 11:213-44; PMID: 8476560; https://doi.org/10.1146/annurev.iy.11.040193.001241 PubMed DOI

Esquivel F, Yewdell J, Bennink J. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med 1992; 175(1):163-8; PMID: 1309852; https://doi.org/10.1084/jem.175.1.163 PubMed DOI PMC

Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T et al.. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology 2016; 5(4):e1105429; PMID: 27141389; https://doi.org/10.1080/2162402X.2015.1105429 PubMed DOI PMC

Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54(3):187-207; PMID: 15309328; https://doi.org/10.1007/s00262-004-0560-6 PubMed DOI PMC

Wang R-F, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184(6):2207-16; PMID: 8976176; https://doi.org/10.1084/jem.184.6.2207 PubMed DOI PMC

Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolić-Zugić J. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188(9):1553-61; PMID: 9802967; https://doi.org/10.1084/jem.188.9.1553 PubMed DOI PMC

McWilliams JA, McGurran SM, Dow SW, Slansky JE, Kedl RM. A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol 2006; 177(1):155-61; PMID: 16785510; https://doi.org/10.4049/jimmunol.177.1.155 PubMed DOI

Brusic V, Bajic VB, Petrovsky N. Computational methods for prediction of T-cell epitopes—a framework for modelling, testing, and applications. Methods 2004; 34(4):436-43; PMID: 15542369; https://doi.org/10.1016/j.ymeth.2004.06.006 PubMed DOI

Cole DK, Edwards ES, Wynn KK, Clement M, Miles JJ, Ladell K, Ekeruche J, Gostick E, Adams KJ, Skowera A et al.. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010; 185(4):2600-10; PMID: 20639478; https://doi.org/10.4049/jimmunol.1000629 PubMed DOI PMC

Koch CP, Perna AM, Pillong M, Todoroff NK, Wrede P, Folkers G, Hiss JA, Schneider G. Scrutinizing MHC-I binding peptides and their limits of variation. PLoS Comput Biol 2013; 9(6):e1003088; PMID: 23754940; https://doi.org/10.1371/journal.pcbi.1003088 PubMed DOI PMC

Messaoudi I, LeMaoult J, Nikolic-Zugic J. The mode of ligand recognition by two peptide: MHC class I-specific monoclonal antibodies. J Immunol 1999; 163(6):3286-94; PMID: 10477598 PubMed

Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O et al.. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002; 188:81-96; PMID: 12445283; https://doi.org/10.1034/j.1600-065X.2002.18808.x PubMed DOI

Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54(6):777-85; PMID: 3261634; https://doi.org/10.1016/S0092-8674(88)91043-4 PubMed DOI

De Bruijn ML, Schumacher TN, Nieland JD, Ploegh HL, Kast WM, Melief CJ. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol 1991; 21(12):2963-70; PMID: 1660811; https://doi.org/10.1002/eji.1830211210 PubMed DOI

Didierlaurent AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet C, Malissen B, Lambrecht BN et al.. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 2014; 193(4):1920-30; PMID: 25024381; https://doi.org/10.4049/jimmunol.1400948 PubMed DOI

Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, Bertin TK, Rodgers JR, Lee B. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 2007; 15(2):378-85; PMID: 17235317; https://doi.org/10.1038/sj.mt.6300031 PubMed DOI

Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012; 20(11):2076-86; PMID: 22828500; https://doi.org/10.1038/mt.2012.137 PubMed DOI PMC